[ad_1]
“The first 2-3 million doses of the Oxford-Irbm-AstraZeneca Covid vaccine should arrive in Italy by the end of November if the ongoing trial progresses positively, after temporary suspension due to a suspicious reaction in a volunteer then it turned out no be related to the candidate vaccine “. This was stated to ANSA by Piero di Lorenzo, president of the Irbm of Pomezia, who collaborated with the Jenner Institute of Oxord University in the development of the vaccine prototype. If there are no critical issues and experimentation will continue as planned, then “the schedule already announced by Health Minister Roberto Speranza will be respected.”
The vaccine experimentation was resumed after the temporary suspension due to a true reaction of one of the 50 thousand volunteers participating in the tests. The volunteer had suffered from spinal inflammation, acute transverse myelitis, which consists of inflammation in one or more adjacent segments of the spinal cord. However, the independent expert panel that examined the matter established within days that this reaction was not related to the inoculation of the candidate vaccine. This experiment, explains di Lorenzo, “is actually carried out in double blindness: this means that neither the doctors nor the patients know which of the volunteers is given the candidate vaccine and which only placebo. Therefore, he concludes, the reaction Suspicious could also occurred in a volunteer who had taken the placebo and not the drug. “
REPRODUCTION RESERVED © Copyright ANSA
[ad_2]
